Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Sci Rep
2022 Dec 07;121:21113. doi: 10.1038/s41598-022-25534-2.
Show Gene links
Show Anatomy links
Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity.
Rodrigues-Junior DM
,
Raminelli C
,
Hassanie H
,
Trossini GHG
,
Perecim GP
,
Caja L
,
Moustakas A
,
Vettore AL
.
???displayArticle.abstract???
Glioblastoma (GBM) is the most aggressive and common primary malignant brain tumor with limited available therapeutic approaches. Despite improvements in therapeutic options for GBM patients, efforts to develop new successful strategies remain as major unmet medical needs. Based on the cytotoxic properties of aporphine compounds, we evaluated the biological effect of 12 compounds obtained through total synthesis of ( ±)-apomorphine hydrochloride (APO) against GBM cells. The compounds 2,2,2-trifluoro-1-(1-methylene-3,4-dihydroisoquinolin-2(1H)-yl)ethenone (A5) and ( ±)-1-(10,11-dimethoxy-6a,7-dihydro-4H-dibenzo[de,g]quinolin-6(5H)-yl)ethenone (C1) reduced the viability of GBM cells, with 50% inhibitory concentration ranging from 18 to 48 μM in patient-derived GBM cultures. Our data show that APO, A5 or C1 modulate the expression of DNA damage and apoptotic markers, impair 3D-gliomasphere growth and reduce the expression of stemness markers. Potential activity and protein targets of A5, C1 or APO were predicted in silico based on PASS and SEA software. Dopamine receptors (DRD1 and 5), CYP2B6, CYP2C9 and ABCB1, whose transcripts were differentially expressed in the GBM cells, were among the potential A5 or C1 target proteins. Docking analyses (HQSAR and 3D-QSAR) were performed to characterize possible interactions of ABCB1 and CYP2C9 with the compounds. Notably, A5 or C1 treatment, but not temozolomide (TMZ), reduced significantly the levels of extracellular ATP, suggesting ABCB1 negative regulation, which was correlated with stronger cytotoxicity induced by the combination of TMZ with A5 or C1 on GBM cells. Hence, our data reveal a potential therapeutic application of A5 and C1 as cytotoxic agents against GBM cells and predicted molecular networks that can be further exploited to characterize the pharmacological effects of these isoquinoline-containing substances.
Alcantara Llaguno,
Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma.
2016, Pubmed
Alcantara Llaguno,
Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma.
2016,
Pubmed
Altinoz,
From epidemiology to treatment: Aspirin's prevention of brain and breast-cancer and cardioprotection may associate with its metabolite gentisic acid.
2018,
Pubmed
Antonini,
Apomorphine infusion in advanced Parkinson disease.
2018,
Pubmed
Arora,
Glioblastoma vs temozolomide: can the red queen race be won?
2019,
Pubmed
Bhat,
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
2020,
Pubmed
Bock,
Mitochondria as multifaceted regulators of cell death.
2020,
Pubmed
Bradshaw,
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme.
2016,
Pubmed
Caja,
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma.
2022,
Pubmed
Caragher,
Monoamines in glioblastoma: complex biology with therapeutic potential.
2018,
Pubmed
Chen,
A restricted cell population propagates glioblastoma growth after chemotherapy.
2012,
Pubmed
Di Chiara,
Pharmacology and neurochemistry of apomorphine.
1978,
Pubmed
El-Bachá,
Mechanisms of apomorphine cytoxicity towards rat glioma C6 cells: protection by bovine serum albumin and formation of apomorphine-protein conjugates.
1999,
Pubmed
Furnari,
Malignant astrocytic glioma: genetics, biology, and paths to treatment.
2007,
Pubmed
Gilbert,
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
2013,
Pubmed
Gimple,
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer.
2019,
Pubmed
Goldwirt,
Irinotecan and temozolomide brain distribution: a focus on ABCB1.
2014,
Pubmed
Hu,
ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays.
2009,
Pubmed
Imura,
The predominant neural stem cell isolated from postnatal and adult forebrain but not early embryonic forebrain expresses GFAP.
2003,
Pubmed
Ishiba,
Investigation of the inhibitory mechanism of apomorphine against MDM2-p53 interaction.
2017,
Pubmed
Jiang,
Cytochrome C-mediated apoptosis.
2004,
Pubmed
Jung,
Apomorphine suppresses TNF-α-induced MMP-9 expression and cell invasion through inhibition of ERK/AP-1 signaling pathway in MCF-7 cells.
2017,
Pubmed
Kang,
The Beclin 1 network regulates autophagy and apoptosis.
2011,
Pubmed
Kashiwada,
Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids.
2005,
Pubmed
Keiser,
Relating protein pharmacology by ligand chemistry.
2007,
Pubmed
Kondo,
Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine.
1990,
Pubmed
Laschinski,
Inhibition of striatal tyrosine hydroxylase by low concentrations of apomorphine.
1984,
Pubmed
Lathia,
Cancer stem cells in glioblastoma.
2015,
Pubmed
Lee,
Apomorphine induces mitochondrial-dysfunction-dependent apoptosis in choriocarcinoma.
2020,
Pubmed
Lee,
Apomorphine facilitates loss of respiratory chain activity in human epithelial ovarian cancer and inhibits angiogenesis in vivo.
2020,
Pubmed
Lee,
Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
2016,
Pubmed
Leng,
Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
2017,
Pubmed
Li,
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma.
2014,
Pubmed
Lin,
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
2014,
Pubmed
Liu,
Structural and mechanistic bases of the anticancer activity of natural aporphinoid alkaloids.
2013,
Pubmed
Liu,
AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research.
2014,
Pubmed
Lorico,
Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma.
2008,
Pubmed
Luo,
Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL.
2010,
Pubmed
Maksoud,
The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.
2021,
Pubmed
Maksoud,
The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies.
2022,
Pubmed
Menyhárt,
Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
2021,
Pubmed
Messaoudi,
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
2015,
Pubmed
Mitchell,
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions.
2021,
Pubmed
Munoz,
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
2015,
Pubmed
Pinheiro,
Reprint of: A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth.
2018,
Pubmed
Ponnala,
Cytotoxicity of aporphines in human colon cancer cell lines HCT-116 and Caco-2: an SAR study.
2011,
Pubmed
Rodrigues-Junior,
Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells.
2020,
Pubmed
,
Echinobase
Schaich,
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
2009,
Pubmed
Singh,
Recent advances in anti-HIV natural products.
2010,
Pubmed
Stupp,
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
2009,
Pubmed
Stévigny,
Cytotoxic and antitumor potentialities of aporphinoid alkaloids.
2005,
Pubmed
Wang,
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
2017,
Pubmed
Wang,
DNA damage and apoptosis.
2001,
Pubmed
Weller,
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.
2014,
Pubmed
Whirl-Carrillo,
An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.
2021,
Pubmed
Xie,
The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes.
2015,
Pubmed
Zhuang,
Structural insights into the human D1 and D2 dopamine receptor signaling complexes.
2021,
Pubmed
de Gooijer,
Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.
2018,
Pubmed
